CSPC Innovation Pharmaceutical (SHE:300765) incurred an attributable loss of 26.9 million yuan in the first quarter, compared with an attributable profit of 79.1 million yuan a year prior, a Wednesday Hong Kong filing by parent CSPC Pharmaceutical (HKG:1093) said.
Loss per share in the quarter was 0.0192 yuan, while the company made earnings per share of 0.0676 yuan in the first quarter of 2024.
The pharmaceutical company saw a 9.9% drop in revenue to 472 million yuan in the three months from 524.1 million yuan in the year-ago period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.